Search Videos and More
Video
Reid W. Merryman, MD discusses results of a multicenter phase II trial
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma
Video
Andrew A. Lane, MD, PhD discuss results from a phase 2 Study
Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendtritic cell neoplasm (BPDCN)
Video
Mahasweta Gooptu, MD discusses results from the NMDP-sponsored access expansion Study
Phase 2 Study of post transplant cyclophosphamide-based graft versus host disease prophlaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning
Video
Jorge J. Castillo, MD discusses results from a multicenter phase 2 Study
High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenstrom macroglobulinemia
Video
Omar Nadeem, MD discusses results of the Phase II d-PRISM study
Daratumumab in high-rish MGUS and low-risk smoldering myeloma
News
Twenty-Five Years of Progress in Cancer
As we close out the first quarter of the twenty-first century, it isn’t hard to notice how much the world has changed since the year 2000. Smartphones. Social media. Artificial intelligence.
News
Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants
Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.
Document
Tip Sheet: Medication-Related Osteonecrosis of the Jaw
The Breast Oncology Center developed this reference for providers caring for patients with medication-related osteonecrosis of the jaw in November 2025.
Video
Paolo Tarantino, MD discusses the DATO - Base study
Paolo Tarantino, MD, of Dana-Farber Cancer Institute, presented new findings from the DATO-Base study examining treatment with the ADC Dato-DXd for women with leptomeningeal disease. Breast cancer is the most common cancer linked to this rare but serious condition.
Video
Ann Partridge, MD discusses YES study
Breast cancer survivors who used a novel mobile health intervention to self-manage post-treatment symptoms were able to improve their quality of life and reduce the burden of common symptoms, according to results of the YES study presented by Ann Partridge, MD, of Dana-Farber Cancer Institute.
Video
Stefania Morganti, MD discusses ctDNA study
Ultrasensitive detection of minimal residual disease using ctDNA can help predict the duration of response to HER2 targeted therapy in patients with metastatic breast cancer, according to a study presented by Stefani Morganti, MD, of Dana-Farber Cancer Institute.
Video
Rachel Freedman, MD discusses phase 2 ATOP study
Dana-Farber Cancer Institute's Rachel Freedman, MD, presents results from the phase 2 ATOP study showing older patients with HER2+ breast cancer receiving adjuvant T-DM1 had a favorable 5-year survival with manageable toxicity. ATOP is the 1st adjuvant trial for older patients with HER2+ breast cancer in the United States.